AbbVie Inc. (ABBV) stock
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3090% above fair value
$292.82−1.73 (-0.59%)
Close on Nov 17, 2026Market cap $517.45BP/E 82.7Yield 2.27%
AbbVie operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
AbbVie's operating cash flow for the twelve months ending Jun 30, 2026 was $19.51B, up 1.2% year over year. For fiscal 2025 it was $19.03B, up 1.2% from the year before. Over ten years it grew 9.7% a year on average. The highest annual figure on record is $24.94B in fiscal 2022.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.03B | +1.2% |
| FY2024 | Dec 31, 2024 | $18.81B | -17.7% |
| FY2023 | Dec 31, 2023 | $22.84B | -8.4% |
| FY2022 | Dec 31, 2022 | $24.94B | +9.5% |
| FY2021 | Dec 31, 2021 | $22.78B | +29.5% |
| FY2020 | Dec 31, 2020 | $17.59B | +32.0% |
| FY2019 | Dec 31, 2019 | $13.32B | -0.8% |
| FY2018 | Dec 31, 2018 | $13.43B | +34.8% |
| FY2017 | Dec 31, 2017 | $9.96B | +41.5% |
| FY2016 | Dec 31, 2016 | $7.04B | -6.6% |
| FY2015 | Dec 31, 2015 | $7.54B | +112.3% |
| FY2014 | Dec 31, 2014 | $3.55B | -43.4% |
| FY2013 | Dec 31, 2013 | $6.27B | -1.2% |
| FY2012 | Dec 31, 2012 | $6.35B | +1.6% |
| FY2011 | Dec 31, 2011 | $6.25B | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $3.44B | -33.3% |
| Q1 FY2026 | Mar 31, 2026 | $3.83B | +134.2% |
| Q4 FY2025 | Dec 31, 2025 | $5.22B | -26.0% |
| Q3 FY2025 | Sep 30, 2025 | $7.02B | +29.0% |
| Q2 FY2025 | Jun 30, 2025 | $5.15B | +126.9% |
| Q1 FY2025 | Mar 31, 2025 | $1.64B | -59.5% |
| Q4 FY2024 | Dec 31, 2024 | $7.05B | +48.3% |
| Q3 FY2024 | Sep 30, 2024 | $5.45B | -28.1% |
| Q2 FY2024 | Jun 30, 2024 | $2.27B | -64.1% |
| Q1 FY2024 | Mar 31, 2024 | $4.04B | -3.6% |
| Q4 FY2023 | Dec 31, 2023 | $4.75B | -36.0% |
| Q3 FY2023 | Sep 30, 2023 | $7.57B | -0.4% |
| Q2 FY2023 | Jun 30, 2023 | $6.32B | +26.3% |
| Q1 FY2023 | Mar 31, 2023 | $4.19B | -14.6% |
| Q4 FY2022 | Dec 31, 2022 | $7.43B | +46.4% |
| Q3 FY2022 | Sep 30, 2022 | $7.60B | -4.2% |
| Q2 FY2022 | Jun 30, 2022 | $5.01B | +2.4% |
| Q1 FY2022 | Mar 31, 2022 | $4.91B | +0.6% |
| Q4 FY2021 | Dec 31, 2021 | $5.08B | +4.6% |
| Q3 FY2021 | Sep 30, 2021 | $7.94B | +36.1% |
| Q2 FY2021 | Jun 30, 2021 | $4.89B | +58.3% |
| Q1 FY2021 | Mar 31, 2021 | $4.88B | +27.8% |
| Q4 FY2020 | Dec 31, 2020 | $4.85B | +48.2% |
| Q3 FY2020 | Sep 30, 2020 | $5.83B | +28.0% |
| Q2 FY2020 | Jun 30, 2020 | $3.09B | +24.7% |
| Q1 FY2020 | Mar 31, 2020 | $3.82B | +26.5% |
| Q4 FY2019 | Dec 31, 2019 | $3.28B | -3.4% |
| Q3 FY2019 | Sep 30, 2019 | $4.56B | +0.7% |
| Q2 FY2019 | Jun 30, 2019 | $2.48B | -13.6% |
| Q1 FY2019 | Mar 31, 2019 | $3.02B | +14.1% |
| Q4 FY2018 | Dec 31, 2018 | $3.39B | +31.3% |
| Q3 FY2018 | Sep 30, 2018 | $4.52B | +38.3% |
| Q2 FY2018 | Jun 30, 2018 | $2.87B | +43.1% |
| Q1 FY2018 | Mar 31, 2018 | $2.65B | +25.8% |
| Q4 FY2017 | Dec 31, 2017 | $2.58B | +67.7% |
| Q3 FY2017 | Sep 30, 2017 | $3.27B | +125.0% |
| Q2 FY2017 | Jun 30, 2017 | $2.00B | – |
| Q1 FY2017 | Mar 31, 2017 | $2.10B | – |
| Q4 FY2016 | Dec 31, 2016 | $1.54B | – |
| Q3 FY2016 | Sep 30, 2016 | $1.45B | – |
See a number that looks wrong?